Rathbones Group’s Takeda Pharmaceutical TAK Stock Holding History

Rathbones Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,931	Closed	-$169K	–	638
2023 Q3	$169K	Buy	+10,931	New	+$169K	﹤0.01%	553

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Rathbones Group's TAK Position: Q4 2023 in Review

Rathbones Group sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 10,931 shares — an estimated $169K sold.

Rathbones Group first reported a position in TAK in Q3 2023 and held it in 1 quarter. The position peaked at $169K in Q3 2023. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Rathbones Group reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Rathbones Group sold 10,931 Takeda Pharmaceutical shares in Q4 2023, an estimated $169K.
Rathbones Group first reported a position in Takeda Pharmaceutical in Q3 2023 and held it in 1 quarter.
Rathbones Group's Takeda Pharmaceutical position peaked at $169K in Q3 2023.
306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Rathbones Group's 13F filing for Q4 2023, filed 13 Feb 2024.